نتایج جستجو برای: pancreatic targeting

تعداد نتایج: 231256  

2016
Sentia Iriana Shahzad Ahmed Jun Gong Alagappan Anand Annamalai Richard Tuli Andrew Eugene Hendifar

Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data have shown that inhibition of mammalian target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition of tumorigenesis in vitro and in vivo. Earl...

Journal: :npj precision oncology 2021

Abstract Pancreatic ductal adenocarcinoma (PDAC), characterized by dense desmoplastic stroma laid down pancreatic stellate cells (PSC), has no reliable diagnostic biomarkers for timely detection. A multi-center cohort of PDAC patients and controls (chronic pancreatitis, intra-ductal papillary neoplasms, gallstones otherwise healthy) donated serum in an ethically approved manner. Serum PTX3 abov...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2016
Amira Elgogary Qingguo Xu Brad Poore Jesse Alt Sarah C Zimmermann Liang Zhao Jie Fu Baiwei Chen Shiyu Xia Yanfei Liu Marc Neisser Christopher Nguyen Ramon Lee Joshua K Park Juvenal Reyes Thomas Hartung Camilo Rojas Rana Rais Takashi Tsukamoto Gregg L Semenza Justin Hanes Barbara S Slusher Anne Le

Targeting glutamine metabolism via pharmacological inhibition of glutaminase has been translated into clinical trials as a novel cancer therapy, but available drugs lack optimal safety and efficacy. In this study, we used a proprietary emulsification process to encapsulate bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), a selective but relatively insoluble glutaminase inhi...

Journal: :Molecular cancer therapeutics 2008
Sven A Lang Philipp Schachtschneider Christian Moser Akira Mori Christina Hackl Andreas Gaumann David Batt Hans J Schlitt Edward K Geissler Oliver Stoeltzing

The Ras/Raf/MEK pathway represents an important oncogenic signaling pathway in gastrointestinal malignancies, including pancreatic cancer. Although activating B-Raf mutations are infrequent in pancreatic cancer, we hypothesized that targeting Raf could be valuable for therapy of this cancer entity. Moreover, as vascular endothelial growth factor receptor 2 (VEGFR2) is involved in tumor angiogen...

حقی آشتیانی, محمدتقی, ربیعی, نیلوفر, فرهمند, فاطمه, محجوب, فاطمه, نجفی, مهری,

Background & Aims: Pancreatic Elastase–1 (EL-1) is a human specific protease enzyme, produced and secreted by pancreatic acinar cells. This enzyme is stable and is not affected by prescriptions of supplement pancreatic enzymes, and it has good connection with pancreatic stimulation function tests. The Purpose of this study is to compare fecal pancreatic elastase–1 concentration in patients wi...

2018
Ting Zhan Xiaodong Huang Xia Tian Xiaoli Chen Yu Ding Hesheng Luo Yadong Zhang

Drug resistance is a major cause of treatment failure in pancreatic cancer. The limited evidence indicates the involvement of miR-455-3p in chemotherapy resistance of cancer. Here we observed by qPCR that miR-455-3p was significantly decreased in pancreatic cancer tissues and cell lines. We then confirmed that the inhibition of miR-455-3p increased cell proliferation and gemcitabine resistance ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Wan-Ching Yen Marcus M Fischer Mark Hynes Jingjiang Wu Edward Kim Lucia Beviglia V Pete Yeung Xiaomei Song Ann M Kapoun John Lewicki Austin Gurney Diane M Simeone Timothy Hoey

PURPOSE We previously showed that targeting Delta-like ligand 4 (DLL4) in colon and breast tumors inhibited tumor growth and reduced tumor initiating cell frequency. In this report, we have extended these studies to pancreatic cancer and probed the mechanism of action in tumor and stromal cells involved in antitumor efficacy. EXPERIMENTAL DESIGN Patient-derived pancreatic xenograft tumor mode...

2016
Xiaoqing Wu Wenhua Tang Rebecca T. Marquez Ke Li Chad A. Highfill Fengtian He Jiqin Lian Jiayuh Lin James R. Fuchs Min Ji Ling Li Liang Xu

Chemo/radio-therapy resistance to the deadly pancreatic cancer is mainly due to the failure to kill pancreatic cancer stem cells (CSCs). Signal transducer and activator of transcription 3 (STAT3) is activated in pancreatic CSCs and, therefore, may be a valid target for overcoming therapeutic resistance. Here we investigated the potential of STAT3 inhibition in sensitizing pancreatic cancer to c...

2012
Li Deng Xingfa Ke Zhiying He Daoqiu Yang Hai Gong Yingying Zhang Xiaolong Jing Jianzhong Yao Jianming Chen

Pancreatic cancer is a highly lethal disease with a 5-year survival rate less than 5% due to the lack of an early diagnosis method and effective therapy. To provide a novel early diagnostic method and targeted therapy for pancreatic cancer, a multifunctional nanoimmunoliposome with high loading of ultrasmall superparamagnetic iron oxides (USPIOs) and doxorubicin (DOX) was prepared by transient ...

Journal: :Scandinavian Journal of Immunology 2021

Pancreatic cancer has been identified as one of the deadliest malignancies because it remains asymptomatic and usually presents in advanced stage. Tumour immune evasion is a well-known mechanism tumorigenesis various forms human malignancies. Chronic inflammation via complex networking inflammatory cytokines local tissue microenvironment dysregulates system support tumour development. Pro-infla...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید